Trust in AstraZeneca Vaccine Fading, Adding to Shortages
Voice of America
Confidence is fading fast in Britain’s AstraZeneca coronavirus vaccine in the wake of regulators identifying last week a link between the shot and a very rare blood disorder. Europeans are refusing the inoculation in rising numbers, prompting more of Europe’s governments to consider buying Russia’s Sputnik V vaccine. Italy, Spain, Germany, Belgium, the Netherlands, Portugal and France have decided to restrict the vaccine to older adults, but they’re encountering rising public resistance to the injection. An opinion poll in Germany suggests more than 40% of Germans would decline the AstraZeneca vaccine.
The governor of the southern Italian region of Puglia, Michele Emiliano, told the La Repubblica newspaper last week that half of his residents are refusing the vaccination. “It will get worse, thanks to the confused way the European drug agency is communicating about the vaccine,” he said. Skepticism about the vaccine also has spread to Africa. The African Union, which represents 55 countries, has abandoned plans to buy the Astra vaccine, which was developed by scientists at the University of Oxford, saying instead it will turn to Johnson & Johnson’s single-shot inoculation. Johnson & Johnson vaccine But now there are concerns following the decision Tuesday by the U.S. Food and Drug Administration to recommend “pausing” the rollout of the Johnson & Johnson vaccine so it can investigate reports of rare cases of blood clots. Officials say they are looking into six reported cases “of a rare and severe type of blood clot” in women aged 18 to 48 who received doses. A total of 6.8 million doses of the single-shot Johnson & Johnson vaccine have been administered in the U.S. The company says “no clear causal link” has been found between their vaccine and the clots. Some African governments were already wary of the AstraZeneco immunization before the link to a blood clotting disorder was confirmed by European Union and British regulators, who have emphasized the potentially fatal side effect is “extremely rare,” with only 84 recorded cases out of 25 million vaccinations. Nonetheless, African governments were disturbed last month when a study published in the New England Journal of Medicine found the Astra vaccine, which has been renamed Vaxzevria for marketing purposes, didn’t offer much protection against mild disease caused by a coronavirus variant that emerged in South Africa. The vaccine’s efficacy rate was just 10 percent in preventing mild illness, according to the study, which didn’t address the bigger question of whether it protected patients against severe illness and hospitalization. Asian reluctance Countries across the Asian Pacific are also becoming reluctant to administer the Astra vaccine, which has been plagued with supply problems, or they are heavily restricting its use. The Australian government has decided to restrict its use to those under the age of 50 and has had to abandon a pledge that everyone in the country would receive a first dose by October. Australian officials say they have doubled the country’s order of the Pfizer vaccine. Australia’s health minister, Brendan Murphy, called the policy change “highly precautionary.” Officials in Hong Kong have decided to rely on other vaccines and to abandon previous orders. South Korea also is restricting its use of the Astra vaccine. Scientists and public health experts are largely frustrated by the burgeoning boycott of a vaccine, though its benefits outweigh the risks. They point out there is a minuscule chance of a fatal blood clot. And they warn that if countries reject the vaccine or people decline an Astra jab, it will have an enormous impact on the global rate of vaccinations, giving the virus even more time and opportunity to mutate and throw up strains that are resident to the current crop of vaccines. Because of the cheapness of the vaccine — it is being sold at production cost price by AstraZeneca, a British-Swedish firm — and the fact it can be stored at normal refrigeration temperatures, unlike the Pfizer and Moderna vaccines — the Astra shot had been earmarked as the workhorse vaccine for the developing world and for price-conscious Europe. AstraZeneca accounted for more than 40 percent of coronavirus vaccine orders signed last year by lower- and middle-income countries. And according to Airfinity, a London-based research firm, Astra’s shot accounted for almost a quarter of the total supply deals signed for 2021, Bloomberg has reported.Chairs are set for missing members of the Bibas family who are held hostage in Gaza at a Passover Seder table April 11, 2024, at Israel's Kibbutz Nir Oz, where a quarter of all residents were killed or captured by Hamas on Oct. 7, 2023. Shlomi Berger sits in his daughter's bedroom in Holon, Israel, April 17, 2024. Osnat Peri, right, whose husband, Haim, is in Hamas captivity, takes part in a Passover Seder commemoration with relatives of hostages held in the Gaza Strip, at the communal dining room at Kibbutz Nir Oz in Israel, April 11, 2024.
FILE - A line of Holstein dairy cows feed through a fence at a dairy farm in Idaho on March 11, 2009. Since March 2024, a strain of avian influenza has been found in dairy cow herds in eight U.S. states. FILE - Researchers collect samples of wildlife, where the H5N1 bird flu virus was detected, at Chilean Antarctic Territory, Antarctica, in this handout photo obtained March 13, 2024. (Instituto Antartico Chileno/Handout via Reuters)
Hannah Gutierrez-Reed, center, prepares for a sentencing hearing in state district court in Santa Fe, New Mexico, April 15, 2024. (Eddie Moore/The Albuquerque Journal via AP, Pool) FILE - A musician plays a violin behind a photograph of cinematographer Halyna Hutchins during a vigil in her honor in Albuquerque, New Mexico, Oct. 23, 2021.
Performers take part in the final dress rehearsal of the flame lighting ceremony for the Paris Olympics, at the Ancient Olympia site, Greece, April 15, 2024. Actress Mary Mina, playing a priestess, hands an olive branch to the first torch bearer, Greek olympic gold medalist Stefanos Douskos, during the final dress rehearsal of the flame lighting ceremony for the Paris Olympics at the Ancient Olympia site, Greece, April 15, 2024. Actress Mary Mina, playing a priestess, lights the flame during the final dress rehearsal of the flame lighting ceremony for the Paris Olympics, at the Ancient Olympia site, Greece, April 15, 2024. Performers take part in the final dress rehearsal of the flame lighting ceremony for the Paris Olympics, at the Ancient Olympia site, Greece, April 15, 2024.